Interactions between the IAP antagonist LCL161 and the histone deacetylase inhibitor (HDACI) panobinostat (LBH589) were examined in human multiple myeloma (MM) cells. LCL161 and panobinostat interacted synergistically to induce apoptosis in diverse MM cell lines including those resistant to bortezomib (PS-R). Similar interactions were observed with other HDACIs (MS-275) or IAP antagonists (birinapant). These events were associated with down-regulation of the non-canonical (but not the canonical) NF-κB pathway and activation of the extrinsic, caspase-8- related apoptotic cascade. Co-exposure of MM cells to LCL161/LBH589 induced TRAF3 up-regulation, TRAF2 and NIK down-regulation, diminished expression of BCL-XL and induction of γH2A.X. Ectopic expression of TRAF2, NIK, or BCL-XL, or shRNA TRAF3 knock-down significantly reduced LCL161/LBH589 lethality, as did ectopic expression of dominant-negative FADD. Stromal/microenvironmental factors failed to diminish LCL161/LBH589-induced cell death. The LCL161/LBH589 regimen significantly increased cell killing in primary CD138+ cells (N = 31) and was particularly effective in diminishing the primitive progenitor cell-enriched CD138-/19+/20+/27+ population (N = 23), but was non-toxic to normal CD34+ cells. Finally, combined LCL161/LBH589 treatment significantly increased survival compared to single-agent treatment in an immunocompetent 5TGM1 murine MM model. Together, these findings argue that LCL161 interacts synergistically with LBH589 in MM cells through a process involving inactivation of the non-canonical NF-κB and activation of the extrinsic apoptotic pathways, up-regulation of TRAF3, and TRAF2/BCL-XL down-regulation. Notably, this regimen overcomes various forms of resistance, is active against primary MM cells, and displays significant in vivo activity. This strategy warrants further consideration in MM.